Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder

Multicenter Assessment of Transdermal Therapy in Overactive Bladder With Oxybutynin TDS (MATRIX)

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00224146

Acronym

MATRIX

Enrollment

2878

Registered

2005-09-22

Start date

2004-05-31

Completion date

2005-05-31

Last updated

2011-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overactive Bladder, Quality of Life, Urinary Incontinence

Keywords

Oxytrol(r), transdermal oxybutynin, overactive bladder

Brief summary

This study evaluates changes in health related quality of life outcomes in patients using Oxytrol(r)

Interventions

DRUGoxybutynin transdermal delivery system (Oxytrol(r))

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult patients with one or more symptom of overactive bladder, including urge urinary incontinence, urgency and/or frequency

Exclusion criteria

* Patients for whom Oxytrol(r) is contraindicated. * Patients treated with Oxytrol(r) prior to participation in this study. * Patients residing in long-term care facilities or nursing homes.

Design outcomes

Primary

Measure	Time frame
Change in health-related quality of life	—

Secondary

Measure	Time frame
Change in other outcomes such as:	—
depression	—
work productivity	—
participant satisfaction	—
effect of enhanced patient education on any of the above outcomes	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026